Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

FLT3-ITD Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand

  • Kumsaen, Piyawan (The Medical Science Program, Graduate School, Khon Kaen University) ;
  • Fucharoen, Goonnapa (Center for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences, Khon Kaen University) ;
  • Sirijerachai, Chittima (Division of Hematology, Department of Internal Medicine, Khon Kaen University) ;
  • Chainansamit, Su-on (Department of Pediatrics, Khon Kaen Hospital) ;
  • Wisanuyothin, Nittaya (Department of Pediatrics, Maharat Nakhon Ratchasima Hospital) ;
  • Kuwatjanakul, Pichayanan (Department of Pediatrics, Udonthani Hospital) ;
  • Wiangnon, Surapon (Division of Hematology, Department of Pediatrics, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

The FLT3-ITD mutation is one of the most frequent genetic abnormalities in acute myeloid leukemia (AML) where it is associated with a poor prognosis. The FLT3-ITD mutation could, therefore, be a potential molecular prognostic marker important for risk-stratified treatment options. We amplified the FLT3 gene at exon 14 and 15 in 52 AML patients (aged between 2 months and 74 years) from 4 referral centers (a university hospital and 3 regional hospitals in Northeast Thailand), using a simple PCR method. FLT3-ITD mutations were found in 10 patients (19.2%), being more common in adults than in children (21.1% vs. 14.3%) and more prevalent in patients with acute promyelocytic leukemia (AML-M3) than AML-non M3 (4 of 10 AML-M3 vs. 6 of 42 AML-non M3 patients). Duplication sequences varied in size-between 27 and 171 nucleotides (median=63.5) and in their location. FLT3-ITD mutations with common duplication sequences accounted for a significant percentage in AML patients in northeastern Thailand. This simple PCR method is feasible for routine laboratory practice and these data could help tailor use of the national protocol for AML.

Keywords

References

  1. Ahmad F, Mandava S, Das BR (2010). Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population. Cancer Invest, 28, 63-73. https://doi.org/10.3109/07357900903095649
  2. Annesley CE, Brown P (2014). The biology and targeting of FLT3 in pediatric leukemia. Front Oncol, 4, 263.
  3. Auewarakul CU, Sritana N, Limwongse C, et al (2005). Mutations of the FLT3 gene in adult acute myeloid leukemia: determination of incidence and identification of a novel mutation in a Thai population. Cancer Genet Cytogenet, 162, 127-34. https://doi.org/10.1016/j.cancergencyto.2005.03.011
  4. Bacher U, Schnittger S, Haferlach T (2010). Molecular genetics in acute myeloid leukemia. Curr Opin Oncol, 22, 646-55. https://doi.org/10.1097/CCO.0b013e32833ed806
  5. Elyamany G, Awad M, Fadalla K, et al (2014). Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. Adv Hematol, 2014, 141360.
  6. Estey EH (2013). Acute myeloid leukemia: 2013 update on riskstratification and management. Am J Hematol, 88, 318-27.
  7. Gilliland DG, Griffin JD (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 1532-42. https://doi.org/10.1182/blood-2002-02-0492
  8. Ishfaq M, Malik A, Faiz M, et al (2012). Molecular characterization of FLT3 mutations in acute leukemia patients in Pakistan. Asian Pac J Cancer Prev, 13, 4581-5. https://doi.org/10.7314/APJCP.2012.13.9.4581
  9. Kainz B, Heintel D, Marculescu R, et al (2002). Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J, 3, 283-9. https://doi.org/10.1038/sj.thj.6200196
  10. Kayser S, Schlenk RF, Londono MC, et al (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114, 2386-92. https://doi.org/10.1182/blood-2009-03-209999
  11. Kindler T, Lipka DB, Fischer T (2010). FLT3 as a therapeutic target in AML: still challenging after all these years. Blood, 116, 5089-102. https://doi.org/10.1182/blood-2010-04-261867
  12. Kiyoi H, Naoe T, Yokota S, et al (1997). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. leukemia study group of the Ministry of Health and Welfare (Kohseisho). Leukemia, 11, 1447-52. https://doi.org/10.1038/sj.leu.2400756
  13. Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752-9. https://doi.org/10.1182/blood.V98.6.1752
  14. Levis M (2013). FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hematol Educ Program, 2013, 220-6.
  15. Louicharoen C, Nuchprayoon I (2005). G6PD Viangchan (871G>A) is the most common G6PD-deficient variant in the Cambodian population. J Hum Genet, 50, 448-52. https://doi.org/10.1007/s10038-005-0276-2
  16. Meshinchi S, Alonzo TA, Stirewalt DL, et al (2006). Clinical implications of FLT3 mutations in pediatric AML. Blood, 108, 3654-61. https://doi.org/10.1182/blood-2006-03-009233
  17. Molica M, Breccia M (2015). FLT3-ITD in acute promyelocytic leukemia: clinical distinct profile but still controversial prognosis. Leuk Res, 39, 397-9. https://doi.org/10.1016/j.leukres.2015.01.004
  18. Moreno I, Martin G, Bolufer P, et al (2003). Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica, 88, 19-24.
  19. Mukda E, Pintaraks K, Sawangpanich R, et al (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. Asian Pac J Cancer Prev, 12, 1827-31.
  20. Noguera NI, Breccia M, Divona M, et al (2002). Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 2185-9. https://doi.org/10.1038/sj.leu.2402723
  21. Nuchprayoon I, Sanpavat S, Nuchprayoon S (2002). Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat, 19, 185.
  22. Poire X, Moser BK, Gallagher RE, et al (2014). Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma, 55, 1523-32. https://doi.org/10.3109/10428194.2013.842985
  23. Port M, Bottcher M, Thol F, et al (2014). Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol, 93, 1279-86. https://doi.org/10.1007/s00277-014-2072-6
  24. Pui CH, Carroll WL, Meshinchi S, et al (2011). Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol, 29, 551-65.
  25. Schnittger S, Schoch C, Dugas M, et al (2002). Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66. https://doi.org/10.1182/blood.V100.1.59
  26. Small D (2006). FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program, 178-84.
  27. Stirewalt DL, Kopecky KJ, Meshinchi S, et al (2006). Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood, 107, 3724-6. https://doi.org/10.1182/blood-2005-08-3453
  28. Stirewalt DL, Radich JP (2003). The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer, 3, 650-65. https://doi.org/10.1038/nrc1169
  29. Suzuki R, Onizuka M, Kojima M, et al (2007). Prognostic significance of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia in an unselected patient population. Int J Hematol, 86, 422-8. https://doi.org/10.1007/BF02984000
  30. Thai Pediatric Oncology Group (2014). Treatment protocol for childhood cancer 2014., Bangkok, Imprint corporation.
  31. Thiede C, Steudel C, Mohr B, et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-35. https://doi.org/10.1182/blood.V99.12.4326
  32. Vempati S, Reindl C, Kaza SK, et al (2007). Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood, 110, 686-94. https://doi.org/10.1182/blood-2006-10-053181
  33. Weisberg E, Barrett R, Liu Q, et al (2009). FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat, 12, 81-9. https://doi.org/10.1016/j.drup.2009.04.001
  34. Wiernik PH (2010). FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol, 8, 429-36, 44.
  35. Xu YY, Gao L, Ding Y, et al (2012). [Detection and clinical significance of FLT3-ITD gene mutation in patients with acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 20, 1312-5.
  36. Yohe S (2015). Molecular Genetic Markers in Acute Myeloid Leukemia. J Clin Med, 4, 460-78. https://doi.org/10.3390/jcm4030460
  37. Yunus NM, Johan MF, Ali Nagi Al-Jamal H, et al (2015). Characterisation and clinical significance of FLT3-ITD and non-ITD in acute myeloid leukaemia patients in Kelantan, Northeast Peninsular Malaysia. Asian Pac J Cancer Prev, 16, 4869-72. https://doi.org/10.7314/APJCP.2015.16.12.4869
  38. Zwaan CM, Meshinchi S, Radich JP, et al (2003). FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 102, 2387-94. https://doi.org/10.1182/blood-2002-12-3627